Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 196

1.

Drugging MYCN oncogenic signalling through the MYCN-PA2G4 binding interface.

Koach J, Holien JK, Massudi H, Carter DR, Ciampa OC, Herath M, Lim T, Seneviratne JA, Milazzo G, Murray JE, McCarroll JA, Liu B, Mayoh C, Keenan B, Stevenson BW, Gorman MA, Bell JL, Doughty L, Hüttelmaier S, Oberthuer A, Fischer M, Gifford AJ, Liu T, Zhang X, Zhu S, Gustafson WC, Haber M, Norris MD, Fletcher JI, Perini G, Parker MW, Cheung BB, Marshall GM.

Cancer Res. 2019 Sep 9. pii: canres.1112.2019. doi: 10.1158/0008-5472.CAN-19-1112. [Epub ahead of print]

PMID:
31501192
2.

JMJD6 is a tumorigenic factor and therapeutic target in neuroblastoma.

Wong M, Sun Y, Xi Z, Milazzo G, Poulos RC, Bartenhagen C, Bell JL, Mayoh C, Ho N, Tee AE, Chen X, Li Y, Ciaccio R, Liu PY, Jiang CC, Lan Q, Jayatilleke N, Cheung BB, Haber M, Norris MD, Zhang XD, Marshall GM, Wang JY, Hüttelmaier S, Fischer M, Wong JWH, Xu H, Perini G, Dong Q, George RE, Liu T.

Nat Commun. 2019 Jul 25;10(1):3319. doi: 10.1038/s41467-019-11132-w.

3.

Heterozygous loss of keratinocyte TRIM16 expression increases melanocytic cell lesions and lymph node metastasis.

Sutton SK, Cheung BB, Massudi H, Tan O, Koach J, Mayoh C, Carter DR, Marshall GM.

J Cancer Res Clin Oncol. 2019 Sep;145(9):2241-2250. doi: 10.1007/s00432-019-02981-5. Epub 2019 Jul 24.

4.

Risk factors for symptomatic venous thromboembolism during therapy for childhood acute lymphoblastic leukemia.

Mateos MK, Trahair TN, Mayoh C, Barbaro PM, Sutton R, Revesz T, Barbaric D, Giles JE, Alvaro F, Mechinaud F, Catchpoole D, Kotecha RS, Dalla-Pozza L, Quinn MCJ, MacGregor S, Chenevix-Trench G, Marshall GM.

Thromb Res. 2019 Jun;178:132-138. doi: 10.1016/j.thromres.2019.04.011. Epub 2019 Apr 11.

PMID:
31030032
5.

Predictors of Success of Phase II Pediatric Oncology Clinical Trials.

Franshaw L, Tsoli M, Byrne J, Mayoh C, Sivarajasingam S, Norris M, Marshall GM, Ziegler DS.

Oncologist. 2019 Aug;24(8):e765-e774. doi: 10.1634/theoncologist.2017-0666. Epub 2019 Feb 26.

PMID:
30808815
6.

Inhibition of polyamine synthesis and uptake reduces tumor progression and prolongs survival in mouse models of neuroblastoma.

Gamble LD, Purgato S, Murray J, Xiao L, Yu DMT, Hanssen KM, Giorgi FM, Carter DR, Gifford AJ, Valli E, Milazzo G, Kamili A, Mayoh C, Liu B, Eden G, Sarraf S, Allan S, Di Giacomo S, Flemming CL, Russell AJ, Cheung BB, Oberthuer A, London WB, Fischer M, Trahair TN, Fletcher JI, Marshall GM, Ziegler DS, Hogarty MD, Burns MR, Perini G, Norris MD, Haber M.

Sci Transl Med. 2019 Jan 30;11(477). pii: eaau1099. doi: 10.1126/scitranslmed.aau1099.

PMID:
30700572
7.

The Avatar Acceptability Study: Survivor, Parent and Community Willingness to Use Patient-Derived Xenografts to Personalize Cancer Care.

Wakefield CE, Doolan EL, Fardell JE, Signorelli C, Quinn VF, Tucker KM, Patenaude AF, Marshall GM, Lock RB, Georgiou G, Cohn RJ.

EBioMedicine. 2018 Nov;37:205-213. doi: 10.1016/j.ebiom.2018.10.060. Epub 2018 Oct 29.

8.

Integration of genomics, high throughput drug screening, and personalized xenograft models as a novel precision medicine paradigm for high risk pediatric cancer.

Tsoli M, Wadham C, Pinese M, Failes T, Joshi S, Mould E, Yin JX, Gayevskiy V, Kumar A, Kaplan W, Ekert PG, Saletta F, Franshaw L, Liu J, Gifford A, Weber MA, Rodriguez M, Cohn RJ, Arndt G, Tyrrell V, Haber M, Trahair T, Marshall GM, McDonald K, Cowley MJ, Ziegler DS.

Cancer Biol Ther. 2018;19(12):1078-1087. doi: 10.1080/15384047.2018.1491498. Epub 2018 Oct 9.

9.

Enrolment in paediatric oncology early-phase clinical trials: The health-care professionals' perspective.

Robertson EG, Mitchell R, Wakefield CE, Lewis P, Cousens N, Marshall GM, Russell SJ, Ziegler DS, Anazodo AC, Trahair TN, Barbaric D, Cohn RJ, Alvaro F, O'Brien TA.

J Paediatr Child Health. 2019 May;55(5):561-566. doi: 10.1111/jpc.14248. Epub 2018 Oct 5.

PMID:
30288839
10.

Brief Report: Potent clinical and radiological response to larotrectinib in TRK fusion-driven high-grade glioma.

Ziegler DS, Wong M, Mayoh C, Kumar A, Tsoli M, Mould E, Tyrrell V, Khuong-Quang DA, Pinese M, Gayevskiy V, Cohn RJ, Lau LMS, Reynolds M, Cox MC, Gifford A, Rodriguez M, Cowley MJ, Ekert PG, Marshall GM, Haber M.

Br J Cancer. 2018 Sep;119(6):693-696. doi: 10.1038/s41416-018-0251-2. Epub 2018 Sep 17.

11.

Protocol for the avatar acceptability study: a multiperspective cross-sectional study evaluating the acceptability of using patient-derived xenografts to guide personalised cancer care in Australia and New Zealand.

Wakefield CE, Doolan EL, Fardell JE, Signorelli C, Quinn VF, Tucker KF, Patenaude AF, Marshall GM, Lock RB, Georgiou G, Cohn RJ.

BMJ Open. 2018 Aug 8;8(8):e024064. doi: 10.1136/bmjopen-2018-024064.

12.

LDHA in Neuroblastoma Is Associated with Poor Outcome and Its Depletion Decreases Neuroblastoma Growth Independent of Aerobic Glycolysis.

Dorneburg C, Fischer M, Barth TFE, Mueller-Klieser W, Hero B, Gecht J, Carter DR, de Preter K, Mayer B, Christner L, Speleman F, Marshall GM, Debatin KM, Beltinger C.

Clin Cancer Res. 2018 Nov 15;24(22):5772-5783. doi: 10.1158/1078-0432.CCR-17-2578. Epub 2018 Jun 20.

PMID:
29925504
13.

Increased Survival for Children With Acute Myeloid Leukemia Results From Improved Postrelapse Treatment.

Vedi A, Mitchell R, Shanmuganathan S, Oswald C, Marshall GM, Trahair T, Sivarajasingam S, Ziegler DS.

J Pediatr Hematol Oncol. 2018 Oct;40(7):541-547. doi: 10.1097/MPH.0000000000001215.

PMID:
29794644
14.

Too many targets, not enough patients: rethinking neuroblastoma clinical trials.

Fletcher JI, Ziegler DS, Trahair TN, Marshall GM, Haber M, Norris MD.

Nat Rev Cancer. 2018 Jun;18(6):389-400. doi: 10.1038/s41568-018-0003-x. Review.

PMID:
29632319
15.

Network Modeling of microRNA-mRNA Interactions in Neuroblastoma Tumorigenesis Identifies miR-204 as a Direct Inhibitor of MYCN.

Ooi CY, Carter DR, Liu B, Mayoh C, Beckers A, Lalwani A, Nagy Z, De Brouwer S, Decaesteker B, Hung TT, Norris MD, Haber M, Liu T, De Preter K, Speleman F, Cheung BB, Marshall GM.

Cancer Res. 2018 Jun 15;78(12):3122-3134. doi: 10.1158/0008-5472.CAN-17-3034. Epub 2018 Apr 2.

16.

Health-related quality of life of survivors of childhood acute lymphoblastic leukemia: a systematic review.

Vetsch J, Wakefield CE, Robertson EG, Trahair TN, Mateos MK, Grootenhuis M, Marshall GM, Cohn RJ, Fardell JE.

Qual Life Res. 2018 Jun;27(6):1431-1443. doi: 10.1007/s11136-018-1788-5. Epub 2018 Jan 25.

PMID:
29372438
17.

Delineation of the frequency and boundary of chromosomal copy number variations in paediatric neuroblastoma.

Ho N, Peng H, Mayoh C, Liu PY, Atmadibrata B, Marshall GM, Li J, Liu T.

Cell Cycle. 2018;17(6):749-758. doi: 10.1080/15384101.2017.1421875.

18.

A risk score including microdeletions improves relapse prediction for standard and medium risk precursor B-cell acute lymphoblastic leukaemia in children.

Sutton R, Venn NC, Law T, Boer JM, Trahair TN, Ng A, Den Boer ML, Dissanayake A, Giles JE, Dalzell P, Mayoh C, Barbaric D, Revesz T, Alvaro F, Pieters R, Haber M, Norris MD, Schrappe M, Dalla Pozza L, Marshall GM.

Br J Haematol. 2018 Feb;180(4):550-562. doi: 10.1111/bjh.15056. Epub 2017 Nov 30.

PMID:
29194562
19.

Discovering cancer vulnerabilities using high-throughput micro-RNA screening.

Nikolic I, Elsworth B, Dodson E, Wu SZ, Gould CM, Mestdagh P, Marshall GM, Horvath LG, Simpson KJ, Swarbrick A.

Nucleic Acids Res. 2017 Dec 15;45(22):12657-12670. doi: 10.1093/nar/gkx1072.

20.

High prevalence of relapse in children with Philadelphia-like acute lymphoblastic leukemia despite risk-adapted treatment.

Heatley SL, Sadras T, Kok CH, Nievergall E, Quek K, Dang P, McClure B, Venn N, Moore S, Suttle J, Law T, Ng A, Muskovic W, Norris MD, Revesz T, Osborn M, Moore AS, Suppiah R, Fraser C, Alvaro F, Hughes TP, Mullighan CG, Marshall GM, Pozza LD, Yeung DT, Sutton R, White DL.

Haematologica. 2017 Dec;102(12):e490-e493. doi: 10.3324/haematol.2016.162925. Epub 2017 Sep 21. No abstract available.

21.

Understanding the school experiences of children and adolescents with serious chronic illness: a systematic meta-review.

Lum A, Wakefield CE, Donnan B, Burns MA, Fardell JE, Marshall GM.

Child Care Health Dev. 2017 Sep;43(5):645-662. doi: 10.1111/cch.12475. Epub 2017 May 23. Review.

PMID:
28543609
22.

Establishing Australian school re-entry service guidelines for children diagnosed with cancer.

Lum A, Donnan B, Wakefield CE, Fardell JE, Marshall GM.

J Paediatr Child Health. 2017 Jun;53(6):529-533. doi: 10.1111/jpc.13563. Epub 2017 May 12. No abstract available.

PMID:
28497503
23.

Health-related quality of life of children on treatment for acute lymphoblastic leukemia: A systematic review.

Fardell JE, Vetsch J, Trahair T, Mateos MK, Grootenhuis MA, Touyz LM, Marshall GM, Wakefield CE.

Pediatr Blood Cancer. 2017 Sep;64(9). doi: 10.1002/pbc.26489. Epub 2017 Mar 6. Review.

PMID:
28266135
24.

The regulatory role of long noncoding RNAs in cancer.

Tang Y, Cheung BB, Atmadibrata B, Marshall GM, Dinger ME, Liu PY, Liu T.

Cancer Lett. 2017 Apr 10;391:12-19. doi: 10.1016/j.canlet.2017.01.010. Epub 2017 Jan 19. Review.

PMID:
28111137
25.

The BET bromodomain inhibitor exerts the most potent synergistic anticancer effects with quinone-containing compounds and anti-microtubule drugs.

Liu PY, Sokolowski N, Guo ST, Siddiqi F, Atmadibrata B, Telfer TJ, Sun Y, Zhang L, Yu D, Mccarroll J, Liu B, Yang RH, Guo XY, Tee AE, Itoh K, Wang J, Kavallaris M, Haber M, Norris MD, Cheung BB, Byrne JA, Ziegler DS, Marshall GM, Dinger ME, Codd R, Zhang XD, Liu T.

Oncotarget. 2016 Nov 29;7(48):79217-79232. doi: 10.18632/oncotarget.12640.

26.

Heterogeneity in mechanisms of emergent resistance in pediatric T-cell acute lymphoblastic leukemia.

Yadav BD, Samuels AL, Wells JE, Sutton R, Venn NC, Bendak K, Anderson D, Marshall GM, Cole CH, Beesley AH, Kees UR, Lock RB.

Oncotarget. 2016 Sep 13;7(37):58728-42. doi: 10.18632/oncotarget.11233.

27.

MYCN and HDAC5 transcriptionally repress CD9 to trigger invasion and metastasis in neuroblastoma.

Fabian J, Opitz D, Althoff K, Lodrini M, Hero B, Volland R, Beckers A, de Preter K, Decock A, Patil N, Abba M, Kopp-Schneider A, Astrahantseff K, Wünschel J, Pfeil S, Ercu M, Künkele A, Hu J, Thole T, Schweizer L, Mechtersheimer G, Carter D, Cheung BB, Popanda O, von Deimling A, Koster J, Versteeg R, Schwab M, Marshall GM, Speleman F, Erb U, Zoeller M, Allgayer H, Simon T, Fischer M, Kulozik AE, Eggert A, Witt O, Schulte JH, Deubzer HE.

Oncotarget. 2016 Oct 11;7(41):66344-66359. doi: 10.18632/oncotarget.11662.

28.

MYCN promotes neuroblastoma malignancy by establishing a regulatory circuit with transcription factor AP4.

Xue C, Yu DM, Gherardi S, Koach J, Milazzo G, Gamble L, Liu B, Valli E, Russell AJ, London WB, Liu T, Cheung BB, Marshall GM, Perini G, Haber M, Norris MD.

Oncotarget. 2016 Aug 23;7(34):54937-54951. doi: 10.18632/oncotarget.10709.

29.

A novel compound which sensitizes BRAF wild-type melanoma cells to vemurafenib in a TRIM16-dependent manner.

Sutton SK, Carter DR, Kim P, Tan O, Arndt GM, Zhang XD, Baell J, Noll BD, Wang S, Kumar N, McArthur GA, Cheung BB, Marshall GM.

Oncotarget. 2016 Aug 9;7(32):52166-52178. doi: 10.18632/oncotarget.10700.

30.

Synthesis, Characterization and Anti-Cancer Activity of Hydrazide Derivatives Incorporating a Quinoline Moiety.

Bingul M, Tan O, Gardner CR, Sutton SK, Arndt GM, Marshall GM, Cheung BB, Kumar N, Black DS.

Molecules. 2016 Jul 14;21(7). pii: E916. doi: 10.3390/molecules21070916.

31.

Acute Sensitivity of Ph-like Acute Lymphoblastic Leukemia to the SMAC-Mimetic Birinapant.

Richmond J, Robbins A, Evans K, Beck D, Kurmasheva RT, Billups CA, Carol H, Heatley S, Sutton R, Marshall GM, White D, Pimanda J, Houghton PJ, Smith MA, Lock RB.

Cancer Res. 2016 Aug 1;76(15):4579-91. doi: 10.1158/0008-5472.CAN-16-0523. Epub 2016 Jun 14.

32.

Polyamine Antagonist Therapies Inhibit Neuroblastoma Initiation and Progression.

Evageliou NF, Haber M, Vu A, Laetsch TW, Murray J, Gamble LD, Cheng NC, Liu K, Reese M, Corrigan KA, Ziegler DS, Webber H, Hayes CS, Pawel B, Marshall GM, Zhao H, Gilmour SK, Norris MD, Hogarty MD.

Clin Cancer Res. 2016 Sep 1;22(17):4391-404. doi: 10.1158/1078-0432.CCR-15-2539. Epub 2016 Mar 24.

33.

Glutathione biosynthesis is upregulated at the initiation of MYCN-driven neuroblastoma tumorigenesis.

Carter DR, Sutton SK, Pajic M, Murray J, Sekyere EO, Fletcher J, Beckers A, De Preter K, Speleman F, George RE, Haber M, Norris MD, Cheung BB, Marshall GM.

Mol Oncol. 2016 Jun;10(6):866-78. doi: 10.1016/j.molonc.2016.02.004. Epub 2016 Mar 2.

34.

High TDP43 expression is required for TRIM16-induced inhibition of cancer cell growth and correlated with good prognosis of neuroblastoma and breast cancer patients.

Kim PY, Tan O, Liu B, Trahair T, Liu T, Haber M, Norris MD, Marshall GM, Cheung BB.

Cancer Lett. 2016 May 1;374(2):315-23. doi: 10.1016/j.canlet.2016.02.021. Epub 2016 Feb 20.

PMID:
26902425
35.

The long noncoding RNA MALAT1 promotes tumor-driven angiogenesis by up-regulating pro-angiogenic gene expression.

Tee AE, Liu B, Song R, Li J, Pasquier E, Cheung BB, Jiang C, Marshall GM, Haber M, Norris MD, Fletcher JI, Dinger ME, Liu T.

Oncotarget. 2016 Feb 23;7(8):8663-75. doi: 10.18632/oncotarget.6675.

36.

Down syndrome and leukemia: insights into leukemogenesis and translational targets.

Mateos MK, Barbaric D, Byatt SA, Sutton R, Marshall GM.

Transl Pediatr. 2015 Apr;4(2):76-92. doi: 10.3978/j.issn.2224-4336.2015.03.03. Review.

37.

The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects.

Shahbazi J, Liu PY, Atmadibrata B, Bradner JE, Marshall GM, Lock RB, Liu T.

Clin Cancer Res. 2016 May 15;22(10):2534-44. doi: 10.1158/1078-0432.CCR-15-1666. Epub 2016 Jan 5.

38.

Therapeutic targeting of the MYC signal by inhibition of histone chaperone FACT in neuroblastoma.

Carter DR, Murray J, Cheung BB, Gamble L, Koach J, Tsang J, Sutton S, Kalla H, Syed S, Gifford AJ, Issaeva N, Biktasova A, Atmadibrata B, Sun Y, Sokolowski N, Ling D, Kim PY, Webber H, Clark A, Ruhle M, Liu B, Oberthuer A, Fischer M, Byrne J, Saletta F, Thwe le M, Purmal A, Haderski G, Burkhart C, Speleman F, De Preter K, Beckers A, Ziegler DS, Liu T, Gurova KV, Gudkov AV, Norris MD, Haber M, Marshall GM.

Sci Transl Med. 2015 Nov 4;7(312):312ra176. doi: 10.1126/scitranslmed.aab1803.

39.

WDR5 Supports an N-Myc Transcriptional Complex That Drives a Protumorigenic Gene Expression Signature in Neuroblastoma.

Sun Y, Bell JL, Carter D, Gherardi S, Poulos RC, Milazzo G, Wong JW, Al-Awar R, Tee AE, Liu PY, Liu B, Atmadibrata B, Wong M, Trahair T, Zhao Q, Shohet JM, Haupt Y, Schulte JH, Brown PJ, Arrowsmith CH, Vedadi M, MacKenzie KL, Hüttelmaier S, Perini G, Marshall GM, Braithwaite A, Liu T.

Cancer Res. 2015 Dec 1;75(23):5143-54. doi: 10.1158/0008-5472.CAN-15-0423. Epub 2015 Oct 15.

40.

MYCN-driven regulatory mechanisms controlling LIN28B in neuroblastoma.

Beckers A, Van Peer G, Carter DR, Gartlgruber M, Herrmann C, Agarwal S, Helsmoortel HH, Althoff K, Molenaar JJ, Cheung BB, Schulte JH, Benoit Y, Shohet JM, Westermann F, Marshall GM, Vandesompele J, De Preter K, Speleman F.

Cancer Lett. 2015 Sep 28;366(1):123-32. doi: 10.1016/j.canlet.2015.06.015. Epub 2015 Jun 26.

41.

AKR1C3 is a biomarker of sensitivity to PR-104 in preclinical models of T-cell acute lymphoblastic leukemia.

Moradi Manesh D, El-Hoss J, Evans K, Richmond J, Toscan CE, Bracken LS, Hedrick A, Sutton R, Marshall GM, Wilson WR, Kurmasheva RT, Billups C, Houghton PJ, Smith MA, Carol H, Lock RB.

Blood. 2015 Sep 3;126(10):1193-202. doi: 10.1182/blood-2014-12-618900. Epub 2015 Jun 26.

42.

Thymosin-β4 is a determinant of drug sensitivity for Fenretinide and Vorinostat combination therapy in neuroblastoma.

Cheung BB, Tan O, Koach J, Liu B, Shum MS, Carter DR, Sutton S, Po'uha ST, Chesler L, Haber M, Norris MD, Kavallaris M, Liu T, O'Neill GM, Marshall GM.

Mol Oncol. 2015 Aug;9(7):1484-500. doi: 10.1016/j.molonc.2015.04.005. Epub 2015 Apr 29.

43.

MYCN amplification confers enhanced folate dependence and methotrexate sensitivity in neuroblastoma.

Lau DT, Flemming CL, Gherardi S, Perini G, Oberthuer A, Fischer M, Juraeva D, Brors B, Xue C, Norris MD, Marshall GM, Haber M, Fletcher JI, Ashton LJ.

Oncotarget. 2015 Jun 20;6(17):15510-23.

44.

Variegated clonality and rapid emergence of new molecular lesions in xenografts of acute lymphoblastic leukemia are associated with drug resistance.

Nowak D, Liem NL, Mossner M, Klaumünzer M, Papa RA, Nowak V, Jann JC, Akagi T, Kawamata N, Okamoto R, Thoennissen NH, Kato M, Sanada M, Hofmann WK, Ogawa S, Marshall GM, Lock RB, Koeffler HP.

Exp Hematol. 2015 Jan;43(1):32-43.e1-35. doi: 10.1016/j.exphem.2014.09.007. Epub 2014 Oct 29.

45.

TRIM16 inhibits proliferation and migration through regulation of interferon beta 1 in melanoma cells.

Sutton SK, Koach J, Tan O, Liu B, Carter DR, Wilmott JS, Yosufi B, Haydu LE, Mann GJ, Thompson JF, Long GV, Liu T, McArthur G, Zhang XD, Scolyer RA, Cheung BB, Marshall GM.

Oncotarget. 2014 Oct 30;5(20):10127-39.

46.

Persistent MRD before and after allogeneic BMT predicts relapse in children with acute lymphoblastic leukaemia.

Sutton R, Shaw PJ, Venn NC, Law T, Dissanayake A, Kilo T, Haber M, Norris MD, Fraser C, Alvaro F, Revesz T, Trahair TN, Dalla-Pozza L, Marshall GM, O'Brien TA.

Br J Haematol. 2015 Feb;168(3):395-404. doi: 10.1111/bjh.13142. Epub 2014 Oct 14.

PMID:
25312094
47.

MYCN-targeting miRNAs are predominantly downregulated during MYCN‑driven neuroblastoma tumor formation.

Beckers A, Van Peer G, Carter DR, Mets E, Althoff K, Cheung BB, Schulte JH, Mestdagh P, Vandesompele J, Marshall GM, De Preter K, Speleman F.

Oncotarget. 2015 Mar 10;6(7):5204-16.

48.

Paternal intake of folate and vitamins B6 and B12 before conception and risk of childhood acute lymphoblastic leukemia.

Bailey HD, Miller M, Greenop KR, Bower C, Attia J, Marshall GM, Armstrong BK, Milne E.

Cancer Causes Control. 2014 Dec;25(12):1615-25. doi: 10.1007/s10552-014-0466-3. Epub 2014 Oct 5.

49.

A pre-clinical model of resistance to induction therapy in pediatric acute lymphoblastic leukemia.

Samuels AL, Beesley AH, Yadav BD, Papa RA, Sutton R, Anderson D, Marshall GM, Cole CH, Kees UR, Lock RB.

Blood Cancer J. 2014 Aug 1;4:e232. doi: 10.1038/bcj.2014.52.

50.

Histone deacetylase 2 and N-Myc reduce p53 protein phosphorylation at serine 46 by repressing gene transcription of tumor protein 53-induced nuclear protein 1.

Shahbazi J, Scarlett CJ, Norris MD, Liu B, Haber M, Tee AE, Carrier A, Biankin AV, London WB, Marshall GM, Lock RB, Liu T.

Oncotarget. 2014 Jun 30;5(12):4257-68.

Supplemental Content

Loading ...
Support Center